Peter‐Andreas Löschmann

1.1k total citations
17 papers, 897 citations indexed

About

Peter‐Andreas Löschmann is a scholar working on Neurology, Cellular and Molecular Neuroscience and Cognitive Neuroscience. According to data from OpenAlex, Peter‐Andreas Löschmann has authored 17 papers receiving a total of 897 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Neurology, 7 papers in Cellular and Molecular Neuroscience and 4 papers in Cognitive Neuroscience. Recurrent topics in Peter‐Andreas Löschmann's work include Neurological disorders and treatments (8 papers), Parkinson's Disease Mechanisms and Treatments (8 papers) and Neuroscience and Neuropharmacology Research (6 papers). Peter‐Andreas Löschmann is often cited by papers focused on Neurological disorders and treatments (8 papers), Parkinson's Disease Mechanisms and Treatments (8 papers) and Neuroscience and Neuropharmacology Research (6 papers). Peter‐Andreas Löschmann collaborates with scholars based in Germany, Denmark and Estonia. Peter‐Andreas Löschmann's co-authors include H. Wachtel, Lechosław Turski, Ullrich Wüllner, Frederico Guilherme Graeff, Milena de Barros Viana, Thomas Klockgether, Thomas Klockgether, Günther Fischer, John A. Kemp and Lance A. Smith and has published in prestigious journals such as Nature, Brain Research and Journal of Neurochemistry.

In The Last Decade

Peter‐Andreas Löschmann

17 papers receiving 870 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter‐Andreas Löschmann Germany 12 643 414 244 85 69 17 897
C. David Marsden United Kingdom 9 385 0.6× 448 1.1× 323 1.3× 124 1.5× 106 1.5× 11 920
Ada Ledonne Italy 16 432 0.7× 185 0.4× 296 1.2× 114 1.3× 116 1.7× 31 783
Jolanta Konieczny Poland 20 655 1.0× 449 1.1× 346 1.4× 102 1.2× 87 1.3× 47 975
R. M. Denney United States 9 425 0.7× 351 0.8× 244 1.0× 69 0.8× 67 1.0× 11 809
B. Guibert France 18 551 0.9× 161 0.4× 351 1.4× 59 0.7× 40 0.6× 34 873
Steven M. Graves United States 17 739 1.1× 406 1.0× 323 1.3× 89 1.0× 86 1.2× 31 1.1k
Peter‐A. Löschmann Germany 11 279 0.4× 185 0.4× 256 1.0× 121 1.4× 119 1.7× 12 653
Elena Bastia Italy 15 420 0.7× 204 0.5× 418 1.7× 159 1.9× 130 1.9× 27 1.1k
Angus Nisbet United Kingdom 10 407 0.6× 236 0.6× 276 1.1× 121 1.4× 44 0.6× 16 692
Ken Perry United States 11 485 0.8× 299 0.7× 236 1.0× 125 1.5× 351 5.1× 17 974

Countries citing papers authored by Peter‐Andreas Löschmann

Since Specialization
Citations

This map shows the geographic impact of Peter‐Andreas Löschmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter‐Andreas Löschmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter‐Andreas Löschmann more than expected).

Fields of papers citing papers by Peter‐Andreas Löschmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter‐Andreas Löschmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter‐Andreas Löschmann. The network helps show where Peter‐Andreas Löschmann may publish in the future.

Co-authorship network of co-authors of Peter‐Andreas Löschmann

This figure shows the co-authorship network connecting the top 25 collaborators of Peter‐Andreas Löschmann. A scholar is included among the top collaborators of Peter‐Andreas Löschmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter‐Andreas Löschmann. Peter‐Andreas Löschmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Riederer, Peter, Toshiharu Nagatsu, Hirohisa Watanabe, et al.. (2025). Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression. Journal of Neural Transmission. 132(6). 743–779. 9 indexed citations
2.
Feist, Eugen, Xenofon Baraliakos, Frank Behrens, et al.. (2022). Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes. Rheumatology and Therapy. 9(2). 621–635. 12 indexed citations
3.
Wassenberg, Siegfried, Rolf Rau, T. Klopsch, et al.. (2022). Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA). Rheumatology and Therapy. 10(1). 117–133. 3 indexed citations
4.
Behrens, Frank, Jörg C. Prinz, Jürgen Jobst, et al.. (2018). Simultaneous Response in Several Domains in Patients with Psoriatic Disease Treated with Etanercept as Monotherapy or in Combination with Conventional Synthetic Disease-modifying Antirheumatic Drugs. The Journal of Rheumatology. 45(6). 802–810. 1 indexed citations
5.
Löschmann, Peter‐Andreas & Gerd Horneff. (2018). Langzeitpharmakovigilanz bei Kinderarzneimitteln. Drug Research. 68(S 01). S8–S9. 1 indexed citations
6.
Gaubitz, M., et al.. (2017). Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study. Clinical Rheumatology. 36(9). 1989–1996. 8 indexed citations
7.
8.
Löschmann, Peter‐Andreas, Lance A. Smith, Ullrich Wüllner, et al.. (2004). Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Experimental Neurology. 187(1). 86–93. 82 indexed citations
9.
Dringen, Ralf, et al.. (1997). Use of Dipeptides for the Synthesis of Glutathione by Astroglia‐Rich Primary Cultures. Journal of Neurochemistry. 69(2). 868–874. 34 indexed citations
10.
Viana, Milena de Barros, Frederico Guilherme Graeff, & Peter‐Andreas Löschmann. (1997). Kainate Microinjection into the Dorsal Raphe Nucleus Induces 5-HT Release in the Amygdala and Periaqueductal Gray. Pharmacology Biochemistry and Behavior. 58(1). 167–172. 56 indexed citations
11.
Klockgether, Thomas, et al.. (1996). Effects of the antiparkinsonian drug budipine on central neurotransmitter systems. European Journal of Pharmacology. 301(1-3). 67–73. 26 indexed citations
12.
13.
Löschmann, Peter‐Andreas, et al.. (1995). Lamotrigine has no antiparkinsonian activity in rat models of Parkinson's disease. European Journal of Pharmacology. 284(1-2). 129–134. 12 indexed citations
14.
Klockgether, Thomas, Peter‐Andreas Löschmann, & Ullrich Wüllner. (1994). New medical and surgical treatments for Parkinsonʼs disease. Current Opinion in Neurology. 7(4). 346–352. 18 indexed citations
15.
16.
Kupsch, Andreas, Peter‐Andreas Löschmann, H. Sauer, et al.. (1992). Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice. Brain Research. 592(1-2). 74–83. 63 indexed citations
17.
Turski, Lechosław, et al.. (1991). Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature. 349(6308). 414–418. 456 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. David Marsden Breakdown of academic impact, for papers by Ada Ledonne Breakdown of academic impact, for papers by Jolanta Konieczny Breakdown of academic impact, for papers by R. M. Denney Breakdown of academic impact, for papers by B. Guibert Breakdown of academic impact, for papers by Steven M. Graves Breakdown of academic impact, for papers by Peter‐A. Löschmann Breakdown of academic impact, for papers by Elena Bastia Breakdown of academic impact, for papers by Angus Nisbet Breakdown of academic impact, for papers by Ken Perry
Rankless by CCL
2026